Eloxx Pharmaceuticals Inc.
ELOX | NASDAQ
$13.45
+$0.27 (+2.05%)
At close: Oct 30, 2026, 4:00 PM ET
$13.90
+$0.45 (+3.35%)
After-hours:
Oct 30, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | 6.36M | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 695K | 960K | 571K |
Gross Profit | n/a | 6.36M | n/a | -695K | -960K | -571K |
Operating Income | -6.44M | -2.47M | -17.29M | -34.42M | -42.35M | -29.44M |
Interest Income | 33K | 27K | 252K | 274K | 8K | 322K |
Pretax Income | -6M | -3.14M | -17.05M | -36.14M | -66.73M | -34.58M |
Net Income | -6M | -3.14M | -17.05M | -36.07M | -66.73M | -34.58M |
Selling & General & Admin | 3.38M | 5.25M | 8.69M | 10M | 18.49M | 14.28M |
Research & Development | 3.06M | 3.58M | 8.6M | 23.73M | 22.9M | 14.59M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 6.44M | 8.83M | 17.29M | 33.72M | 41.39M | 28.87M |
Interest Expense | 1.05M | 1.14M | 1.15M | 1.95M | 1.26M | 1.41M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 6.44M | 8.83M | 17.29M | 34.42M | 42.35M | 29.44M |
Income Tax Expense | n/a | n/a | n/a | -77K | n/a | n/a |
Shares Outstanding (Basic) | 1.12M | 341.71K | 233.69K | 196.94K | 159.01K | 91.19K |
Shares Outstanding (Diluted) | 1.12M | 341.71K | 233.69K | 196.94K | 159.01K | 91.19K |
EPS (Basic) | -5.34 | -9.24 | -72.93 | -183.13 | -419.65 | -379.16 |
EPS (Diluted) | -5.34 | -9.24 | -72.93 | -183.13 | -419.65 | -379.16 |
EBITDA | -4.95M | -1.84M | -15.09M | -33.5M | -64.51M | -28.87M |
EBIT | -4.95M | -2M | -15.9M | -34.19M | -65.47M | -29.44M |
Depreciation & Amortization | n/a | 164K | 809K | 695K | 960K | 571K |
Add to Watchlist
Select watchlists to add or remove ELOX